A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2004
11/04/2004	WO2003103662A3 Inhibitors of glycoprotein vi
11/04/2004	WO2003078431A8 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
11/04/2004	WO2003077847A3 Substituted amides
11/04/2004	WO2003060091A3 Selective melanin-concentrating hormone type -1 receptor agonists
11/04/2004	WO2003029420A3 Apo-2 ligand variants and uses thereof
11/04/2004	WO2002092013A3 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/04/2004	US20040220403 For therapy and prophylaxis of Tachykinin-mediated diseases
11/04/2004	US20040220402 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
11/04/2004	US20040220280 Sertraline hydrochloride polymorphs
11/04/2004	US20040220277 Enantiomeric amphetamine compositions
11/04/2004	US20040220274 Synergistic mixture of neurokinin receptor antagonist and phosphodiesterase inhibitor
11/04/2004	US20040220257 modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing said complex to compound such as Spiro [Cyclopentane-1,5'-[5H]Dibenzo [a,d]Cyclohepten]-2-one, 10', 11'-dihydro-3-methylene-
11/04/2004	US20040220244 PHOSPHOLIPASE INHIBITORS; use of inhibitor compositions in mammals to relieve sick conditions accompanied by enhanced PLA(2) activity such as inflammation, asthma, rhinitis, bronchitis, pneumonia, adult respiratory distress syndrome, inflammatory intestine disorder, Crohn's disease
11/04/2004	US20040220234 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
11/04/2004	US20040220230 transfroming growth factor antagonist; therapy for urogenital disorders, cardiovascular disorders
11/04/2004	US20040220225 Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications
11/04/2004	US20040220223 Novel human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
11/04/2004	US20040220213 Zolpidem hemitartrate
11/04/2004	US20040220212 Zolpidem hemitartrate
11/04/2004	US20040220211 Zolpidem hemitartrate
11/04/2004	US20040220210 therapy of insomia, sleep disorders
11/04/2004	US20040220205 Parkinson's disease; restless leg syndrome; sexual disorders
11/04/2004	US20040220204 mixture of fatty ester, alkylene carbonate, butylene glycol, diethylene glycol, monoalkyl ether and thickeners
11/04/2004	US20040220203 Method and composition for potentiating an opiate analgesic
11/04/2004	US20040220202 antiinflammatory agents; central nervous system disorders; controlling cell proliferation, cell differentiation; anticancer agents; antidepressants
11/04/2004	US20040220200 Compositions useful as protein kinase inhibitors
11/04/2004	US20040220194 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
11/04/2004	US20040220184 Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
11/04/2004	US20040220175 (Pyrido/thieno) - [f] - oxazepine-5-one derivatives
11/04/2004	US20040220173 central nervous system disorders; psychological disorders; Parkinson's disease; Huntington's disease ; sleep disorders
11/04/2004	US20040220171 anticoagulants; immunomoderators; antiinflammatory agents
11/04/2004	US20040220149 Nerve cell survival promoters containing cyclic phosphatidic acid derivative
11/04/2004	US20040220133 Composition and method for inhibiting platelet aggregation
11/04/2004	US20040220132 Treatment of neurodegenerative disease through intracranial delivery of siRNA
11/04/2004	US20040220112 administering 2-(N-Methylsulfonamido-2-aminophenyl)-N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide as an anti-pruritic agent; antihyperalgesics; analgesics; central nervous system side effect reduction
11/04/2004	US20040220096 Method and compositions for treating dopaminergic and gabanergic disorders
11/04/2004	US20040220092 G-protein coupled receptors
11/04/2004	US20040220079 Inhibitors of Memapsin 2 and use thereof
11/04/2004	US20040220077 Therapy for neuropathic pain
11/04/2004	US20040219632 T1r3 a novel taste receptor
11/04/2004	US20040219238 Prophylactic agent for enhancement of nerve growth factor production for treatment or prevention comprising an aqueous mushroom extract (xanthohumol or salts) ; neurodegenerative diseases, Alzheimer*s disease, and nervoxanthohumol andus system disorders; foods, beverages, feeds;
11/04/2004	US20040219233 the crude plant extract solvent extracted with a polar or nonpolar solvent; neurodegenerative diseaes, Alzheimer's and Parkinson's diseases, strokes; health foods, powders, tablets, capsules or beverages
11/04/2004	US20040219230 Compositions for preparing external carbon dioxide agents
11/04/2004	US20040219229 Migraine relief composition and methods of using and forming same
11/04/2004	US20040219220 Therapeutic agents
11/04/2004	US20040219213 Oral pulsed dose drug delivery system
11/04/2004	US20040219207 Drug preparation comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
11/04/2004	US20040219202 Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety
11/04/2004	US20040219201 Tempamine compositions and methods of use
11/04/2004	US20040219191 Use of a dopamine agonist with a short half-life for treating illnesses which can be treated by dopaminergic means
11/04/2004	US20040219172 In situ administering botulinum toxins
11/04/2004	US20040219150 Uses of mammalian cytokine; related reagents
11/04/2004	US20040219148 comprising an agent that targets an interleukin-15 receptor and a second agent that inhibits a costimulatory signal transmitted between a T cell and an antigen-presenting cell; treating autoimmune diseases, AIDS, vascular injuries or organ, tissue or cell transplant recipients
11/04/2004	US20040219146 Prevention and treatment of amyloidogenic disease
11/04/2004	US20040219144 administering an anti-human NGF monoclonal antibody capable of binding hNGF with an affinity in the nanomolar range, and inhibiting the binding of hNGF to human TrkA (hTrkA) in vivo, wherein said antibody has no significant adverse effect on the immune system
11/04/2004	DE19930625B4 Verfahren zur Herstellung von Thiuramdisulfiden A process for preparing thiuram disulfides
11/04/2004	CA2809164A1 Postnatal stem cells and uses thereof
11/04/2004	CA2523232A1 (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease
11/04/2004	CA2522805A1 Phenacyl 2-hydroxy-3-diaminoalkanes
11/04/2004	CA2522803A1 Substituted pyrimidinones and pyrimidinthiones as crf antagonists
11/04/2004	CA2522687A1 Pyrazole derivatives as phosphodiesterase 4 inhibitors
11/04/2004	CA2522649A1 Treatment of conditions involving amyloid plaques
11/04/2004	CA2522631A1 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
11/04/2004	CA2518839A1 (piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists
11/04/2004	CA2518700A1 Muscarinic agonists
11/04/2004	CA2518324A1 Muscarinic agonists
11/03/2004	EP1473303A1 Novel proteins and dnas thereof
11/03/2004	EP1473295A1 Fused bicyclic pyrimidine derivatives
11/03/2004	EP1473289A1 Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
11/03/2004	EP1473032A1 Use of taurine, homotaurine and/or methionine for inducing analgesia or anesthesia
11/03/2004	EP1472544A2 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
11/03/2004	EP1472540A2 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908
11/03/2004	EP1472514A2 Method of preparing delta-9 tetrahydrocannabinol
11/03/2004	EP1472377A2 Genetic polymorphisms in the preprotachykinin gene
11/03/2004	EP1472376A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
11/03/2004	EP1472364A2 Truncated aggrecanase molecules
11/03/2004	EP1472351A2 Amino acid sequences capable of facilitating penetration across a biological barrier
11/03/2004	EP1472341A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects
11/03/2004	EP1472273A2 Compositions and methods for the treatement of immune related diseases
11/03/2004	EP1472269A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/03/2004	EP1472267A2 Rna interference mediated inhibition of protein tyrosine phosphatase type iva (prl3) gene expression using short interfering nucleic acid (sina)
11/03/2004	EP1472257A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
11/03/2004	EP1472256A1 Piperidine derivatives
11/03/2004	EP1472255A1 Aza-arylpiperazines
11/03/2004	EP1472253A1 Sulphonyl compounds with 5 -ht6 receptor affinity
11/03/2004	EP1472252A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
11/03/2004	EP1472251A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
11/03/2004	EP1472250A1 Anticholinergic agents, method for producing the same and use thereof as medicaments
11/03/2004	EP1472245A2 Heteroaryl compounds useful as inhibitors of gsk-3
11/03/2004	EP1472244A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
11/03/2004	EP1472243A1 Piperidine derivatives and their use as antagonists of tachykinins
11/03/2004	EP1472241A1 Cytoprotective benzofuran derivatives
11/03/2004	EP1472240A1 Drechslera anole derivatives, method for the production and use thereof
11/03/2004	EP1472237A1 Catechol bioisosteres
11/03/2004	EP1472236A1 Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
11/03/2004	EP1472230A2 Ansamycins having improved pharmacological and biological properties
11/03/2004	EP1472225A2 2-piperazine-pyridines useful for treating pain
11/03/2004	EP1472224A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
11/03/2004	EP1472223A1 Gamma secretase inhibitors
11/03/2004	EP1472222A1 Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases

1 ... 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 ... 1833